{"retracted":false,"update":{"timestamp":1409184000000,"doi":"10.1007/s10549-014-3107-3","type":"correction"},"doi":"10.1007/s10549-014-3042-3","journal":"Breast Cancer Research and Treatment","publisher":"Springer Nature","title":"Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer"}
